Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eiger BioPharmaceuticals

1.73
0.0000
Volume:- -
Turnover:- -
Market Cap:2.55M
PE:-0.03
High:1.73
Open:1.73
Low:1.73
Close:1.73
52wk High:14.34
52wk Low:1.10
Shares:1.48M
Float Shares:1.27M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-50.7794
EPS(LYR):-50.7794
ROE:-367.00%
ROA:-56.45%
PB:-0.18
PE(LYR):-0.03

Loading ...

Sep 09, 2024

Major Issues Report

Form 8-K - Current report
Sep 04, 2024

Major Issues Report

Form 8-K - Current report
Sep 03, 2024

Major Issues Report

Form 8-K - Current report
Aug 26, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Aug 02, 2024

Major Issues Report

Form 8-K - Current report
Aug 01, 2024

Major Issues Report

Form 8-K - Current report
Jul 16, 2024

Major Issues Report

Form 8-K - Current report
Jul 10, 2024

Major Issues Report

Form 8-K - Current report
Jul 01, 2024

Beneficial Ownership Change

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Jul 01, 2024

Major Issues Report

Form 8-K - Current report
Jun 21, 2024

Major Issues Report

Form 8-K - Current report
Jun 14, 2024

Major Issues Report

Form 8-K - Current report
May 28, 2024

Major Issues Report

Form 8-K - Current report
May 10, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
May 08, 2024

Major Issues Report

Form 8-K - Current report
May 02, 2024

Major Issues Report

Form 8-K - Current report
Apr 29, 2024

[Rev.]Annual Report

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Apr 25, 2024

Delisting

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
Apr 08, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Apr 03, 2024

Major Issues Report

Form 8-K - Current report